VXRT – Vaxart, Inc.
Float Short %
9.33
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
-0.02
EPS Last/This Y
0.04
EPS This/Next Y
-0.05
Price
0.56
Target Price
4.67
Analyst Recom
Performance Q
-15.61
Upside
N/A
Beta
1.14
Ticker: VXRT
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | VXRT | 0.669 | N/A | N/A | 0 |
| 2026-01-26 | VXRT | 0.6601 | N/A | N/A | 0 |
| 2026-01-27 | VXRT | 0.6477 | N/A | N/A | 0 |
| 2026-01-28 | VXRT | 0.64 | N/A | N/A | 0 |
| 2026-01-29 | VXRT | 0.61 | N/A | N/A | 0 |
| 2026-01-30 | VXRT | 0.5589 | N/A | N/A | 0 |
| 2026-02-02 | VXRT | 0.591 | N/A | N/A | 0 |
| 2026-02-03 | VXRT | 0.6162 | N/A | N/A | 0 |
| 2026-02-05 | VXRT | 0.6485 | N/A | N/A | 0 |
| 2026-02-09 | VXRT | 0.6068 | N/A | N/A | 0 |
| 2026-02-10 | VXRT | 0.5859 | N/A | N/A | 0 |
| 2026-02-11 | VXRT | 0.5787 | N/A | N/A | 0 |
| 2026-02-12 | VXRT | 0.563 | N/A | N/A | 0 |
| 2026-02-13 | VXRT | 0.535 | N/A | N/A | 0 |
| 2026-02-17 | VXRT | 0.5439 | N/A | N/A | 0 |
| 2026-02-18 | VXRT | 0.538 | N/A | N/A | 0 |
| 2026-02-19 | VXRT | 0.5558 | N/A | N/A | 0 |
| 2026-02-20 | VXRT | 0.59 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-23 | VXRT | 0.66 | -5.6 | - | -0.29 |
| 2026-01-26 | VXRT | 0.67 | -5.6 | - | -0.29 |
| 2026-01-27 | VXRT | 0.66 | -5.6 | - | -0.29 |
| 2026-01-28 | VXRT | 0.65 | -5.6 | - | -0.29 |
| 2026-01-29 | VXRT | 0.64 | -5.6 | - | -0.29 |
| 2026-01-30 | VXRT | 0.61 | -5.6 | - | -0.29 |
| 2026-02-02 | VXRT | 0.58 | -5.6 | - | -0.29 |
| 2026-02-03 | VXRT | 0.61 | -5.6 | - | -0.29 |
| 2026-02-04 | VXRT | 0.64 | -5.6 | - | -0.29 |
| 2026-02-05 | VXRT | 0.63 | -5.6 | - | -0.29 |
| 2026-02-06 | VXRT | 0.62 | -5.6 | - | -0.29 |
| 2026-02-09 | VXRT | 0.61 | -5.6 | - | -0.29 |
| 2026-02-10 | VXRT | 0.61 | -5.6 | - | -0.29 |
| 2026-02-11 | VXRT | 0.59 | -5.6 | - | -0.29 |
| 2026-02-12 | VXRT | 0.57 | -5.6 | - | -0.29 |
| 2026-02-13 | VXRT | 0.56 | -5.6 | - | -0.29 |
| 2026-02-17 | VXRT | 0.57 | -5.6 | - | -0.29 |
| 2026-02-18 | VXRT | 0.56 | -5.6 | - | -0.29 |
| 2026-02-19 | VXRT | 0.55 | -5.6 | - | -0.29 |
| 2026-02-20 | VXRT | 0.56 | -5.6 | - | -0.29 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
No data found
Last Quarter Act. EPS
-0.04
Avg. EPS Est. Current Quarter
-0.1
Avg. EPS Est. Next Quarter
-0.07
Insider Transactions
4.29
Institutional Transactions
Beta
1.14
Average Sales Estimate Current Quarter
2
Average Sales Estimate Next Quarter
2
Fair Value
Quality Score
20
Growth Score
37
Sentiment Score
16
Actual DrawDown %
95
Max Drawdown 5-Year %
-97.2
Target Price
4.67
P/E
Forward P/E
PEG
P/S
1.54
P/B
1.6
P/Free Cash Flow
EPS
-0.26
Average EPS Est. Cur. Y
-0.29
EPS Next Y. (Est.)
-0.34
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
Return on Equity vs Sector %
-218.5
Return on Equity vs Industry %
-201
EPS 1 7Days Diff
EPS 1 30Days Diff
0.05
EBIT Estimation
Vaxart, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 105
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
stock quote shares VXRT – Vaxart, Inc. Stock Price stock today
news today VXRT – Vaxart, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VXRT – Vaxart, Inc. yahoo finance google finance
stock history VXRT – Vaxart, Inc. invest stock market
stock prices VXRT premarket after hours
ticker VXRT fair value insiders trading